The global epidermal growth factor receptor inhibitor market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factors that are accelerating the growth of the global epidermal growth factor receptor inhibitor market include growing incidences of cancer globally, along with the increasing geriatric population and lifestyle changes. Epidermal growth factor inhibitors (EGFRI) is the first targeted cancer therapy, which has become an essential treatment for many advanced-stage epithelial cancers. In comparison to conventional chemotherapies, these agents have the superior ability to target cancer cells, further offering a better safety profile to the patients.

Epidermal growth factor receptor (EGFR) inhibitors are medicines that slow down or stop EGFR’s activity, a protein found on the surface of some normal cells, by binding to its certain part. EGFR or epidermal growth factor receptor causes cells to divide upon binding to it by signalling pathways that control cell division and survival, leading to the growth of normal cells. Certain mutations in EGFR are known to be vulnerable and can lead to the growth of cancer cells.

The global epidermal growth factor receptor inhibitor market analysis includes some of the key market players such as Amgen Inc., AstraZeneca, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., and Novartis AG, among others. To maintain a strong position in the market, these market players are adopting various strategic moves, such as product launches, partnerships, collaborations, and mergers and acquisitions. For instance, in April 2021, Takeda announces US FDA grants priority review for a new drug application for Mobocertinib (TAK-788) as a treatment for EGFR Exon20 Insertion+ metastatic non-small cell lung cancer.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered
• Regions Covered- Globally

Competitive Landscape: Amgen Inc., AstraZeneca, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., and Novartis AG, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Epidermal Growth Factor Receptor Inhibitor Market by Segment

By Type

• Lung Cancer

• Colorectal Cancer

• Breast Cancer

• Others

By Application 

• Hospital

• Research Institutes and Institutions

• Clinic

• Other

Global Epidermal Growth Factor Receptor Inhibitor Market by Region